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Abstract
Background: Acute exposure of ethanol (alcohol) inhibits NMDA receptor function. Our previous study showed
that acute ethanol inhibited the pressor responses induced by NMDA applied intrathecally; however, prolonged
ethanol exposure may increase the levels of phosphorylated NMDA receptor subunits leading to changes in
ethanol inhibitory potency on NMDA-induced responses. The present study was carried out to examine whether
acute ethanol exposure influences the effects of ketamine, a noncompetitive NMDA receptor antagonist, on spinal
NMDA-induced pressor responses.
Methods: The blood pressure responses induced by intrathecal injection of NMDA were recorded in urethane-
anesthetized rats weighing 250-275 g. The levels of several phosphorylated residues on NMDA receptor GluN1
subunits were determined by western blot analysis.
Results: Intravenous injection of ethanol or ketamine inhibited spinal NMDA-induced pressor responses in a dose-
dependent and reversible manner. Ketamine inhibition of NMDA-induced responses was synergistically potentiated
by ethanol when ethanol was applied just before ketamine. However, ketamine inhibition was significantly reduced
when applied at 10 min after ethanol administration. Western blot analysis showed that intravenous ethanol
increased the levels of phosphoserine 897 on GluN1 subunits (pGluN1-serine 897), selectively phosphorylated by
protein kinase A (PKA), in the lateral horn regions of spinal cord at 10 min after administration. Intrathecal
administration of cAMPS-Sp, a PKA activator, at doses elevating the levels of pGluN1-serine 897, significantly
blocked ketamine inhibition of spinal NMDA-induced responses.
Conclusions: The results suggest that ethanol may differentially regulate ketamine inhibition of spinal NMDA
receptor function depending on ethanol exposure time and the resulting changes in the levels of pGluN1-serine
897.
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Background
Ethanol has several effects on the central nervous sys-
tem, such as intoxication, tolerance, and withdrawal.
Although these mechanisms are still not well under-
stood, many evidences suggest an important role of the
glutamate neurotransmitter system in ethanol effects
[1-3]. It has been repeatedly reported that ethanol
antagonizes central effect of glutamate by acting at
NMDA (N-methyl-D-asparate) receptors, a subtype of
ionotropic glutamate receptors, at pharmacologically
relevant concentrations [4,5]. The ability of ethanol to
inhibit NMDA-activated current is linearly related to its
potency for causing intoxication [6]. NMDA receptors
are composed of 7 subunits including a GluN1 subunit,
a family of GluN2 subunits (A, B, C, D), and two GluN3
subunits (A and B) [7]. NMDA receptor function is
regulated by several kinases and phosphatases. There are
several serine residues on GluN1 subunit. The serine
residues 896 and 897 on GluN1 subunit are specifically
phosphorylated by protein kinase C (PKC) and cAMP-
dependent protein kinases (PKA), respectively [8].
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Sympathetic preganglionic neurons (SPNs), located in
thoracolumbar spinal cord, are the final site where sym-
pathetic activity is integrated within the central nervous
system [9]. SPNs provide projections to sympathetic
ganglia and adrenal medulla, whose activation elicits an
increase in peripheral sympathetic activity and the
underlying cardiovascular responses. Our previous stu-
dies showed intrathecal injection of NMDA into the T7-
T9 segments of spinal cord may cause an increase in
blood pressure resulting from the activation of NMDA
receptors in SPNs; intravenous injection of ethanol
selectively inhibited the NMDA-induced pressor
responses [10]. We further demonstrated that prolonged
application of ethanol may increase the phosphorylated
levels of NMDA receptors by activating signaling path-
ways and subsequently regulate (counteract) ethanol
inhibition of the NMDA receptor function [11], which
may contribute to the development of acute ethanol tol-
erance. We suggest that depending on exposure time
and the resulting alteration of the phosphorylated levels
of NMDA receptors, acute ethanol may have differential
influences on NMDA receptor function. Whether etha-
nol intake differentially modulates the inhibitory effects
of NMDA receptor antagonists on NMDA receptor
function remains unclear. The present study was under-
taken to examine the hypothesis that acute ethanol
exposure may affect the inhibitory effects of ketamine, a
non-competitive NMDA receptor channel blocker, on
the responses of NMDA receptors in spinal sympathetic
neurons using an in vivo model established previously;
the magnitude of increases in blood pressure induced by
intrathecal injection of NMDA was used as an index for
responses of NMDA receptors in vivo.
Methods
Animals
Sprague-Dawley (SD) rats purchased from BioLASCO
Co., LTD. (Taipei, Taiwan) were used to establish a
breeding colony at the Laboratory Animal Center, Tzu
Chi University, Taiwan. Adult male rats weighing 250-
270 g selected from the colony were used in the present
study. All procedures were carried out in accordance
with the guidelines of the Institutional Animal Care and
Use Committee of Tzu Chi University. To avoid unne-
cessary sacrifice and suffering, the number of animal
used was minimized, and anesthetics were used
throughout the experiment.
Determination of blood ketamine and ethanol levels
To avoid perturbing the blood pressure recording, blood
ketamine and ethanol concentrations were measured in
another group of male rats under the same conditions
as the experimental ones. The rats were anaesthetized
with urethane. The right femoral vein was cannulated
for intravenous injection of ketamine (2 mg/kg or 4 mg/
kg) or ethanol (0.025 g or 0.16 g). Ketamine (1 ml/kg)
or ethanol (1 ml) at known concentrations was injected
into the femoral vein in 100 seconds. Blood sample of
0.2 ml was withdrawn from the right femoral artery at
10 min and 40 min after intravenous injection. Plasma
ketamine concentrations were measured by a gas chro-
matography mass spectrometer coupled to mass detec-
tor (Hewlett Packard GC 6890 with MS 5973) equipped
with an autosampler and a HP-5MS capillary column
(12.5 m × 0.20 mm i.d. 0.33 μm film thickness) (Agilent
Technologies, Palo Alto, CA) was used for GC-MS ana-
lysis [12]. Blood ethanol concentrations were determined
by an alcohol diagnostic kit available commercially
(Diagnostic Chemicals Limited, Oxford, CT); the rate of
increase in absorbance at 340 nm is recorded with a
spectrophotometer (Beckman DU650).
Intrathecal administration and blood pressure
measurement
Procedures for intrathecal administration to anesthetized
rats were similar to those described previously [10,13].
The rats were anaesthetized with urethane (1.2 g/kg, i.
p.). Additional urethane (0.3 g/kg, i.p.) was applied if the
rats responded to tail pinch or to intrathecal insertion
of polyethylene tubing. The left femoral artery was can-
nulated with a polyethylene tubing (PE 50) and con-
nected to a pressure transducer with its output to a
Gould EasyGraf Recorder (TA420) for recording of
blood pressure. The signals from the recorder were sent
to a data acquisition system (MP 100, BIOPAC System,
Inc.) for continuous recording of blood pressure, and
the built-in function of the acquisition system provides
simultaneous measurements of mean arterial pressure
(MAP). The right femoral vein was cannulated for intra-
venous injection of ketamine or ethanol. Ketamine (1
ml/kg) at known concentrations was injected into the
femoral vein in 100 seconds. Rats were mounted in a
stereotaxic header and implanted with a spinal catheter
for intrathecal injection. A slit was made in the atlanto-
occipital membrane and the catheter (PE-10 tubing) was
inserted down into the spinal subarachnoid space so
that the tip was placed in the vicinity of T7-T9 segment.
The reagents at known concentrations were injected
intrathecally at a volume of 10 μL, which was followed
by 10 μL of saline to wash in the agent. As a negative
control, intrathecal saline did not elicit any significant
changes in blood pressure. NMDA was applied at inter-
vals of 30 min. NMDA or other chemicals at known
concentrations were dissolved in saline and injected
with a microsyringe pump (KDS 100). After NMDA-
induced responses were stable over two consecutive
tests, experiments were then carried out. Firstly, to
examine whether ketamine or ethanol affected NMDA-
Keng et al. Journal of Biomedical Science 2012, 19:11
http://www.jbiomedsci.com/content/19/1/11
Page 2 of 12
induced responses, ketamine or ethanol was injected
intravenously 10 min before the next application of
NMDA. Secondly, to examine the effects of ethanol on
ketamine inhibition of NMDA-induced responses, keta-
mine was applied immediately or at 10 min or 30 min
after intravenous injection of ethanol; NMDA was
applied 10 min after administration of ketamine.
Thirdly, to examine the effects of pretreatment with
PKA activators on modulation of ketamine effects, the
activators was applied intrathecally 10 min prior to
intravenous ketamine; NMDA was applied 10 min and
40 min after administration of ketamine.
Western blot analysis
The procedure for Western blot analysis of spinal cord
tissue was similar to that described in earlier studies
[11,14]. Rats were anaesthetized by intraperitoneal injec-
tion of urethane (1.2 g/kg). A group of 3 rats was used
to determine the levels of several phosphorylated resi-
dues on NMDA receptor subunits following administra-
tion of ethanol or PKA activators. For determination of
the effects of ethanol, a control rat was sacrificed after
the surgery without administration of ethanol; one rat
each was sacrificed at 10 and 30 min following intrave-
nous injection of ethanol. For each dose tested, the
above experiments were repeated 4-5 times. For deter-
mination of the effects of PKA activators, a control rat
was sacrificed at 10 min after intrathecal injection of sal-
ine; one each rat was sacrificed at 10 min after intrathe-
cal injection of cAMPS-Sp (0.5 and 5 nmol). The
thoracic segments of spinal cord were removed immedi-
ately after cardiac perfusion with normal saline contain-
ing protease inhibitors (Complete protease inhibitor
cocktail tablets, Roche Diagnostics, GmbH). Coronal
1000 μm-thick sections from T7-T9 segments of spinal
cord were prepared and quickly frozen by cold spray
(FREEZE 75; CRC Industry Europe NV, Zele, Belgium).
The lateral horn regions of the slices from each rat were
punched out by a tissue puncher (0.75 mm in diameter).
The isolated tissues were frozen in liquid nitrogen and
stored at -85°C until use. The tissue was homogenized
in 60 μL of lysis buffer (0.32 M sucrose, 1 mM EDTA
and 1 mTIU·mL-1 aprotinin) with a homogenizer (Glas-
Col, Terre Haute, IN) under ice bath. SDS was added to
the sample to a final concentration of 0.1%, and 20 μg
of protein was electrophoresed and transferred onto a
nitrocellulose (NC) membrane. After NC membrane
blocking and washing, blots were probed with primary
antibody, rabbit anti-GluN1 polyclonal antibody (1:800,
Upstate Biotechnology Inc., Lake Placid, NY, USA) and
rabbit anti-pGluN1 antisera (serine 896, 1:1500 and ser-
ine 897, 1:1500, Upstate Biotechnology Inc.) in TBS-T
containing 5% skimmed milk powder overnight at 4°C
on a 2D shaker. The blot was then incubated with
secondary goat anti-rabbit (1:2000, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA, USA) antibody conjugated
to horseradish peroxidase, which was measured with
Western Blotting Luminol Reagent (Santa Cruz Biotech-
nology, Santa Cruz, CA). The specific protein bands
were visualized using the enhanced chemiluminescence
(ECL) reagents. The chemiluminescent signal was
detected by X-ray film (Fuji Photo Film Co., Ltd.,
Tokyo), and the intensity of the bands was digitalized by
scanner and analysed with UN-SCAN-IT gel software
version 6.1 for Windows (Silk Scientific Corporation,
Orem, UT, USA). Protein concentrations were deter-
mined by bicinchoninic acid method (Sigma Co.) using
bovine albumin as standard.
Chemicals and statistical analysis
cAMPS-Sp triethylammonium salt, a PKA activator, was
obtained from Tocris Cookson Ltd. (Bristol, UK). Etha-
nol was purchased from Riedel-de Haen (Deisenhofen,
Germany). NMDA, ketamine, aprotinin and other
reagents used for Western blot analysis were purchased
from Sigma Co. (St. Louis, Missouri, USA). Stock solu-
tions were prepared in distilled water; further dilutions
were made in saline. The reagents for electrophoresis
were obtained from Bio-Rad Laboratories (Richmond,
CA).
Data are presented as mean ± SEM and were plotted
and analysed statistically with GraphPad Prism version
4.0 for Windows, GraphPad Software (San Diego, CA).
The time-effect relationship of ethanol or ketamine on
NMDA-induced pressor responses was analysed using
repeated measure ANOVA followed by Newman-Keuls
post-test. The effects of prior administration of ethanol
or pretreatment with cAMPS-Sp on ketamine action at
different times after administration of ketamine were
analysed using two-way ANOVA followed by Bonferroni
post-test. The statistical evaluation of western blots was
analysed using one-way ANOVA followed by Newman-
Keuls post-test. P < 0.05 was considered statistically
significant.
Results
Ketamine inhibition of spinal NMDA-induced pressor
responses
Resting mean arterial pressure (MAP) of the urethane-
anesthetized rats was 80.2 ± 4.3 mmHg (n = 26). As in
our previous study [10], the MAPs increased following
intrathecal injection (1, and 2 nmol, 10 μL) of NMDA
in a dose-dependent manner, which were 14.3 ± 2.5 (n
= 6), and 26.5 ± 2.3 (n = 16) mmHg in magnitudes fol-
lowing the applications of 1 and 2 nmol of NMDA,
respectively. Consecutive intrathecal administration of
NMDA (2 nmol) at intervals of 30 min elicited reprodu-
cible increase in MAP. Intravenous injection of
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ketamine (2 and 4 mg/kg) alone did not cause signifi-
cant changes in MAP. However, NMDA-induced
pressor effects were dose-dependently attenuated by
intravenous administration of ketamine. Representative
recording of ketamine inhibition of spinal NMDA-
induced pressor response is illustrated in Figure 1a. The
time course of percentage changes in NMDA-induced
pressor responses and the corresponding blood concen-
trations of ketamine are illustrated in Figure 1b and 1c,
respectively. The decline level of blood ketamine over
time was accompanied by a comparable degree of reduc-
tions in ketamine inhibition of pressor responses
induced by NMDA after a single injection of ketamine;
NMDA-induced pressor responses decreased by 31%
and 45% when blood ketamine concentrations were
about 195 and 460 ng/mL at 10 min after intravenous
injection of 2 mg/kg and 4 mg/kg of ketamine,
respectively.
Ethanol inhibition of spinal NMDA-induced pressor
responses
Similar to the results in our previous reports [10,11],
spinal NMDA-induced pressor responses were dose-
dependently attenuated by intravenous administration of
Figure 1 Intravenous injection of ketamine dose-dependently inhibited pressor effects induced by intrathecal NMDA. (a) Representative
recordings of changes in blood pressure induced by an intrathecal injection of NMDA (2 nmol, indicated by an arrow) and the changes in
NMDA-induced pressor responses at 10 and 40 min after a single intravenous injection of ketamine (2 or 4 mg/kg). NMDA was applied
intrathecally every 30 min. (b and c) Bar graphs show the time course of the percentage changes in NMDA-induced increases in mean arterial
pressure (MAP, b) and blood ketamine concentration (c) following intravenous injection of two doses of ketamine (2 and 4 mg/kg). The peak
magnitude of NMDA-induced increase in MAP immediately prior to application of ketamine is taken as control (100%).*Significant difference
from control analyzed using the repeated measure ANOVA followed by Newman-Keuls post-test.
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a bolus of ethanol (Figure 2). Intravenous injection of
low dose of ethanol (0.025 g) did not caused significant
changes in NMDA-induced pressor effects at 10 min
after injection when blood ethanol concentration was
about 12.7 mg/dL. NMDA-induced pressor responses
decreased by 36% when blood ethanol concentrations
were about 94.6 mg/dL at 10 min after intravenous
injection of higher dose of ethanol (0.16 g). The decline
level of blood ethanol over time was accompanied by a
comparable degree of reductions in ethanol inhibition of
NMDA-induced pressor responses.
Ethanol potentiated ketamine inhibition of spinal NMDA-
induced pressor responses
Ethanol (0.025 g) applied alone had little effects on
NMDA-induced responses. However, ethanol (0.025 g)
significantly potentiated ketamine inhibition of NMDA-
induced pressor effects when ethanol was applied just
before ketamine (Figure 3a, b). Intravenous injection of
ethanol (0.16 g) followed by ketamine (2 or 4 mg/kg)
caused a strong inhibition of NMDA-induced pressor
effects at 10 min after the injection (Figure 3c); the
degree of inhibition induced by combined administra-
tion of ethanol and ketamine was greater than the sum
of that induced by ethanol or ketamine alone (Figure 3b,
c). These results revealed that ethanol synergistically
potentiated ketamine inhibition of NMDA-induced
responses.
Ketamine inhibition of spinal NMDA-induced pressor
responses was reduced at 10 min after administration of
ethanol
The degree of inhibition by ketamine (2 and 4 mg/kg) of
NMDA-induced pressor effects was examined immedi-
ately (0 min) or at 10 min or 30 min after intravenous
injection of ethanol (0.16 g). The degree of ketamine
inhibition of NMDA-induced pressor effects at 10 min
after intravenous ethanol was significantly less than that
at 0 and 30 min (Figure 4). NMDA-induced responses
decreased by 92%, 55%, and 90% while ketamine (2 mg/
kg) was applied at 0 min, 10 min, and 30 min after
injection of ethanol (0.16 g), respectively; NMDA-
induced responses decreased by 100%, 63%, and 96%
while ketamine (4 mg/kg) was applied at 0 min, 10 min,
and 30 min after ethanol (0.16 g), respectively. These
results showed a reduction of ketamine and/or ethanol
inhibition at 10 min after administration of ethanol.
Ethanol increased the levels of phosphoserine 897 on the
GluN1 subunit in the lateral horn regions of spinal cord
at 10 min after administration
We used western blot analysis to determine the levels of
phosphoserine 896 on GluN1 subunit (pGluN1-serine
896) and phosphoserine 897 on GluN1 subunits
(pGluN1-serine 897), and the protein contents of GluN1
subunits in the lateral horn regions of spinal cord. Intra-
venous injection of ethanol (0.025 g) had little effects on
the levels of pGluN1-serine 897 (Figure 5a). Higher
doses of ethanol (0.16 g and 0.32 g) caused a significant
increase in the level of pGluN1-serine 897 in a dose-
dependent manner at 10 min after the administration of
ethanol (Figure 5b, c); the increase lasted for over 30
min following administration of high dose (0.32 g) of
ethanol. The level of pGluN1-serine 896 did not change
over time after administration of lower doses of ethanol
(0.025 g, 0.16 g), but decreased at 10 min after adminis-
tration of high dose (0.32 g) of ethanol (Figure 5).
Intrathecal a PKA activator, at doses increased the levels
of pGluN1-serine 897, blocked ketamine inhibition
Intrathecal cAMPS-Sp (0.5 nmol), a PKA activator, had
no significant effects on the levels of pGluN1-serine 897
in the lateral horn of the spinal cord at 10 min post-
injection; Higher dose of cAMPS-Sp (5 nmol) signifi-
cantly increased the levels of pGluN1-serine 897 (Figure
6a). Intrathecal injection of cAMPS-Sp (5 nmol) had
negligible effects on blood pressure and on spinal
NMDA-induced pressor responses applied 10 min
Figure 2 Bar graphs show the time course of blood ethanol concentrations (left part) and percentage changes in NMDA-induced
increases in MAP (right part) at 10 min and 40 min following intravenous injection of two doses of ethanol (0.025 g and 0.16 g). The
peak magnitude of NMDA-induced increase in MAP immediately prior to application of ethanol is taken as control (100%). *Significant difference
from control analyzed using the repeated measure ANOVA followed by Newman-Keuls post-test.
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Figure 3 (a) Representative recordings of changes in blood pressure induced by an intrathecal injection of NMDA (2 nmol) and the
changes in NMDA-induced pressor effects at 10 and 40 min after an intravenous injection of ethanol (EtOH, 0.025 g) immediately
followed by ketamine (2 mg/kg, left panel; 4 mg/kg, right panel). (b) Bar graphs show percentage changes in NMDA-induced increases in
MAP at 10 min and 40 min after intravenous injection of ethanol (0.025 g) alone, ketamine alone (2 mg/kg, left; 4 mg/kg, right), and ethanol
(0.025 g) immediately followed by ketamine (2 mg/kg, left; 4 mg/kg, right). The peak magnitude of NMDA-induced increase in MAP immediately
prior to application of ethanol and/or ketamine is taken as control (100%). (c) Similar to (b) except that higher dose (0.16 g) of ethanol was
injected. *P < 0.05 versus ethanol or ketamine alone group analyzed using two-way ANOVA followed by Bonferroni post-test.
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before administration of NMDA (n = 3). However,
intrathecal injection of cAMPS-Sp 10 min before intra-
venous injection of ketamine dose-dependently blocked
the inhibitory effects of ketamine on spinal NMDA-
induced pressor responses (Figure 6b, c).
Discussion
The present study showed for the first time that ethanol
differentially regulate, depending on ethanol exposure
time and the underlying changes in the levels of
pGluN1-serine 897, ketamine inhibition of spinal
NMDA receptor-mediated responses. In addition, our
study provided the first evidence that an increase in the
levels of pGluN1-serine 897 reduced the inhibitory
potency of ketamine on NMDA receptor function.
Our previous study found that intravenous ethanol, at
doses without noticeable effects on intrathecal AMPA-
mediated pressor responses, significantly inhibited
NMDA-mediated pressor responses, indicating NMDA
receptors are main targets of ethanol in sympathetic
neurons of spinal cord [10]. The present study demon-
strated that intravenous ethanol inhibited spinal
NMDA-induced pressor responses as in our previous
findings. In addition, we also found that intravenous
ketamine inhibited NMDA-induced pressor effects in a
blood concentration-dependent and reversible manner.
An interesting finding was that intravenous injection of
ethanol just before ketamine may produce synergetic
effects on the inhibition of NMDA-induced responses, i.
e. the combined inhibition is greater than the sum of
individual inhibition. The synergistic inhibition may be
of greater concern with respect to fetal brain damage
because NMDA receptors play an important role during
the developmental period of synaptogenesis [15,16].
Because of the ability of ketamine to produce mild-alter-
ing effects it is frequently abused. Abuse of ketamine
mixed with other drugs is increasingly common in rave
party [17,18], where intake of ketamine would be com-
bined with that of ethanol. There were reports of the
lethality from mixed-drug intoxication involving keta-
mine and ethanol [19]. The current findings showing a
potentiated inhibition of ketamine by ethanol on
NMDA receptor function may provide a molecular
mechanism for the neurotoxicity induced by combined
intake of ethanol and ketamine.
By utilizing a patch clamp technique to examine
NMDA-activated currents, ketamine may inhibit the
NMDA receptor by two distinct mechanisms. First,
ketamine blocks the open channel and thereby reduces
channel mean open time; secondly, ketamine may bind
to the closed receptor and decrease the frequency of
channels opening by an allosteric mechanism. Low con-
centrations of ketamine predominantly caused closed-
channel blockade, whereas both open and closed chan-
nel blockade occurred at higher ketamine concentration
[20]. Ethanol is well known to inhibit NMDA receptor
function. However, the precise site and the action
mechanism underlying alcohol inhibition have not been
established [21]. Ethanol inhibits NMDA receptors in a
noncompetitive manner and does not appear to act by
interfering with either glutamate or glycine binding. By
studying cells transfected with NMDA receptor subu-
nits, acute alcohol treatment has been shown to interact
with several transmembrane domains of NMDA recep-
tors because alterations in certain amino acids of
NMDA receptor subunits changed alcohol sensitivity
[22,23]. Alcohol may also act at a site located in a
domain exposed to the extracellular environment [24].
In addition, ethanol sensitivity of NMDA receptors may
be modulated by discrete sites within the TM3 and
TM4 domains of the GluN1 subunit [25]. These studies
suggest a putative binding site of NMDA receptor to
Figure 4 Bar graphs show percentage changes in NMDA-induced increases in MAP 10 min and 40 min after intravenous injection of
ketamine (2 mg/kg, left part; 4 mg/kg, right part) applied immediately (0 min) or at 10 min and 30 min after intravenous injection of
ethanol (0.16 g). The peak magnitude of NMDA-induced increase in MAP immediately prior to application of ethanol and/or ketamine is taken
as control (100%). *Statistically significant difference between groups analyzed using two-way ANOVA followed by Bonferroni post-test.
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ethanol. The current study demonstrated that ethanol
may synergistically potentiate ketamine inhibition of
NMDA-induced responses, suggesting that the binding
site of ethanol may be different to that of ketamine in
NMDA receptors and both binding sites may interact
with each other in regulating NMDA receptor function.
Actually, a recent study also showed that ifenprodil, a
selective NMDA receptor GluN2B subunit antagonist,
may enhance the anti-hyperalgesic effect of ketamine
[26].
Figure 5 (a) Left panel: western blot analysis of the levels of phosphoserine 896 on GluN1 subunit (pGluN1-serine 896),
phosphoserine 897 on GluN1 subunit (pGluN1-serine 897), and GluN1 subunit (GluN1) in lateral horn regions of T7-T9 segments of
rat spinal cord without (control) and at 10 min and 30 min after intravenous injection of ethanol (EtOH, 0.025 g). The percentage
changes in the ratio of pGluN1 (serine 896 and serine 897) to GluN1 are shown in the right panel. The ratio of pGluN1 to GluN1 in rats without
administration of ethanol is taken as control (100%). Panels (b) and (c) are similar to panel (a) except that 0.16 g and 0.32 g ethanol were
injected, respectively. Values denote mean + SEM from 4-5 separate experiments. *Statistically significant difference from control analyzed by
one-way ANOVA followed by Newman- Keuls post-test.
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Figure 6 (a) Left panel: Western blot analysis of the levels of phosphoserine 897 on the GluN1 subunit (pGluN1-serine 897, top) and
GluN1 subunit (GluN1, bottom) in lateral horn regions of spinal cord at 10 min after intrathecal injection of saline (control) and
cAMPS-Sp (0.5 and 5 nmol). The percentage changes in the ratio of pGluN1-serine 897 to GluN1 are shown in the right panel. Values denote
mean + SEM from three separate experiments. *Significant difference from control (100%). (b) Representative recordings of changes in blood
pressure induced by an intrathecal injection of NMDA (2 nmol) before (control) and at 10 min and 40 min after intravenous injection of
ketamine (2 mg/kg, left panel; 4 mg/kg, right panel) following pretreatment with cAMPS-Sp (5 nmol); cAMPS-Sp was applied intrathecally 10 min
before the administration of ketamine. (c) Bar graphs show percentage changes in NMDA-induced increases in MAP 10 min and 40 min after
intravenous injection of ketamine (2 mg/kg, left part; 4 mg/kg, right part) following intrathecal pretreatment with various doses of cAMPS-Sp.
*Statistically significant difference from ketamine alone group (without pretreatment with cAMPS-Sp) analyzed using two-way ANOVA followed
by Bonferroni post-test.
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Phosphorylation is important in direct and indirect
modulation of NMDA receptors. The serine residue 897
on GluN1 subunit is specifically phosphorylated by
PKA; the serine residue 890 and 896 is phosphorylated
by PKC; the tyrosine residue 1336 on GluN2B subunit
(pGluN2B-tyrosine 1336) is specifically phosphorylated
by protein tyrosine kinases [27]. Acute and chronic
exposure of ethanol affects the function of specific intra-
cellular signaling pathways, including PKA, PKC, and
tyrosine kinase signaling pathways [28,29]. Some kinases
such as fyn tyrosine kinase, PKC and PKA are able to
reduce NMDA receptor sensitivity to acute ethanol
[30-32]. Our previous study demonstrated that continu-
ous intravenous ethanol infusion may activate PKA,
PKC, and Src tyrosine kinase leading to increases in the
levels of pGluN1-serine 896, pGluN1-serine 897, and
pGluN2B-tyrosine 1336, respectively, in the lateral horn
of the spinal cord [11]. We also showed that the
increase in the levels of pGluN1-serine 896 and
pGluN2B-tyrosine 1336, but not pGluN1-serine 897,
may counteract ethanol inhibition of spinal NMDA-
induced pressor responses and be responsible for acute
ethanol tolerance during prolonged ethanol exposure. In
the current study, we found that a single bolus intrave-
nous injection of low dose of ethanol would cause an
increase in the levels of pGluN1-serine 897, but not
pGluN1-serine 896, a short period of time (10 min)
after the injection when blood ethanol concentrations
were about 90 mg/dL (0.09%). The increases in the
levels of pGluN1-serine 897 induced by ethanol may
reduce the inhibitory potency of ketamine as supported
by our results showing that intrathecal cAMPS-Sp, a
PKA activator, at doses elevating the levels of pGluN1-
serine 897 significantly blocked ketamine inhibition of
spinal NMDA-induced responses. The results provide
the first in vivo evidence that PKA signaling pathways
may participate in the regulation of ketamine inhibition
of NMDA receptor function. In addition, our results
have an important implication that alteration of the
phosphorylated levels of NMDA receptor subunits may
have influence on the effects of NMDA receptor antago-
nists. A recent study showed that inhibition of cAMP
hydrolysis by phosphodiesterase inhibitors significantly
reversed ketamine-induced anesthesia in mice [33],
further supporting the idea that cAMP signaling path-
ways are involved in the regulation of ketamine effects.
Our previous study showed that the immunoreactivity
to pGluN1-serine 896 (regulated by PKC) was decreased
at 10 min but increased at 40 min in neurons of inter-
mediolateral cell column following continuous ethanol
infusion [11]. The present study also showed that
pGluN1-serine 896 was significantly reduced in the lat-
eral horn regions of spinal cord at 10 min after adminis-
tration of higher dose of ethanol. Ethanol is widely
reported to regulate the function of PKC [34,35]. PKC
may regulate NMDA receptor function through non-
receptor tyrosine kinase [36]. It has been suggested that
ethanol-induced tyrosine dephosphorylation of NMDA
receptor subunits plays an important role in mediating
the inhibitory effects of ethanol on NMDA receptor
function [37]. It is possible that decreases in the levels
of pGluN1-serine 896 may contribute to the inhibitory
effects of ethanol on spinal NMDA-induced responses.
Further work is required to establish this. In addition to
NMDA receptors, GABA receptors are another impor-
tant target for ethanol action. Ethanol increases GABA
receptor function in several brain regions [3,38]. Ethanol
inhibition of NMDA receptor activity has been sug-
gested to be both directly through actions on the
NMDA receptors, and indirectly, possibly through
potentiation of GABA receptor activity [39]. Therefore,
the possibility that ethanol regulation of NMDA-
induced responses was secondary to the effects of etha-
nol on other targets such as GABA receptors cannot be
ruled out.
Heavier alcohol consumption is associated with cardi-
ovascular dysfunction such as hypertension and stroke
[40]. However, epidemiological studies have also showed
that moderate consumption of alcohol is associated with
reduced risk of coronary artery disease [41]. A positive
relationship between alcohol consumption and blood
pressure is well-established in epidemiologic studies
[42,43]. Though the mechanisms underlying alcohol-
induced hypertension remain unclear, alteration of cen-
tral sympathetic activity has been suggested to partici-
pate in alcohol-induced changes in blood pressure
[44,45]. It is likely that differential regulation by ethanol
of NMDA receptor function in spinal sympathetic neu-
rons may contribute to ethanol regulation of cardiovas-
cular function, although further studies are required to
clarify this.
Conclusion
In summary, our results indicate that simultaneous
intake of ethanol and ketamine may produce synergisti-
cally inhibitory effects on NMDA receptor function.
However, intake of ethanol a certain period of time
prior to ketamine may reduce the inhibitory effects of
ketamine by activating PKA signaling pathways resulting
in elevated levels of pGluN1-serine 897.
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